{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:49:12Z","timestamp":1762163352421,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 DK082863"],"award-info":[{"award-number":["U01 DK082863"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1053\/j.gastro.2013.11.028","type":"journal-article","created":{"date-parts":[[2013,11,22]],"date-time":"2013-11-22T23:45:37Z","timestamp":1385163937000},"page":"15-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects"],"prefix":"10.1053","volume":"146","author":[{"given":"Suna","family":"Yapali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna S.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2013.11.028_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2013.11.028_bib2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2013.11.028_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.11.028_bib4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.23346","article-title":"Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function","volume":"50","author":"Lange","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib5","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1523-1755.2004.00866.x","article-title":"Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies","volume":"66","author":"Izzedine","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.gastro.2013.11.028_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.gastro.2008.10.026","article-title":"2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B","volume":"136","author":"Liaw","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.11.028_bib7","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hep.23044","article-title":"Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil","volume":"50","author":"Ha","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib8","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","article-title":"Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B","volume":"35","author":"Gara","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2013.11.028_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","article-title":"Antiviral drug-induced nephrotoxicity","volume":"45","author":"Izzedine","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.gastro.2013.11.028_bib10","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.11.028_bib11","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1016\/S0168-8278(09)60913-2","article-title":"Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from Globe and 015 studies in chronic hepatitis B patients","volume":"50","author":"Hsu","year":"2009","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2013.11.028_bib12","first-page":"43","article-title":"Prolonged efficacy of 3 years of continous telbivudine treatment in Chinese chronic hepatitis B","volume":"3","author":"Jia","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2013.11.028_bib13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","article-title":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B","volume":"20","author":"Wang","year":"2013","journal-title":"J Viral Hepatol"},{"key":"10.1053\/j.gastro.2013.11.028_bib14","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J Viral Hepatol"},{"key":"10.1053\/j.gastro.2013.11.028_bib15","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2013.11.028_bib16","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.11.028_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib18","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.gastro.2012.05.037","article-title":"Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B","volume":"143","author":"Lok","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2013.11.028_bib19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus\u00a0lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2013.11.028_bib21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1053\/j.gastro.2013.11.028_bib22","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib23","article-title":"A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study","author":"Tsai","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2013.11.028_bib24","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1002\/hep.22841","article-title":"Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy","volume":"49","author":"Tenney","year":"2009","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2013.11.028_bib25","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/S0168-8278(12)60552-2","article-title":"2-year results of telbivudine roadmap study verify optimal efficacy and\u00a0safety results in HBeAg-positive chronic hepatitis B patients","volume":"56","author":"Piratvisuth","year":"2012","journal-title":"J Hepatol"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513016764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508513016764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:41:40Z","timestamp":1762162900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508513016764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0016508513016764"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2013.11.028","relation":{},"ISSN":["0016-5085"],"issn-type":[{"type":"print","value":"0016-5085"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential Benefit of Telbivudine on Renal Function Does Not Outweigh Its High Rate of Antiviral Drug Resistance and Other Adverse Effects","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2013.09.031","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}